Low Dose Methoxyflurane and Out-Patient Aesthetic Surgery and Facial Filler

An Open-Label Study to Assess the Efficacy and Safety of Low Dose Methoxyflurane (PENTHROX®) for Pain Control During Outpatient Aesthetic Surgeries and Facial Filler Injections

Status

Withdrawn

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04292808

Enrollment

Registered

2020-03-03

Start date

2020-07-31

Completion date

2021-07-31

Last updated

2023-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Brief summary

The aim of the study is to generate real-world evidence on the effectiveness, safety and additional parameters of low dose methoxyflurane (PENTHROX®) in: aesthetic surgeries (eg. hair transplant, upper blepharoplasty, otoplasty, upper brow lift, and mentoplasty) and facial filler injections \[eg. hyaluronic acid (HA) and Sculptra®\] in an outpatient aesthetic practice. This will be an open-label study, with a total of 60 patients undergoing a planned outpatient aesthetic surgery or filler injection (30 patients in each group).

Interventions

DRUGMethoxyflurane

Methoxyflurane inhaler during out-patient aesthetics surgery or facial dermal fillers.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

1. Conscious adult patients: ≥ 18 years of age 2. Patient is scheduled for an outpatient anesthetic surgery (eg. hair transplant, upper blepharoplasty, otoplasty, upper brow lift, and mentoplasty) or a facial filler injection (eg. HA, and Sculptra®). 3. Patient should understand the nature of the study and provide written informed consent 4. Patient is able to follow all study requirements and procedures and complete required questionnaires

Exclusion criteria

1. An altered level of consciousness, due to any cause, including head injury, drugs, or alcohol 2. Clinically significant renal impairment 3. Women of child bearing potential who are pregnant or peri partum, including labour 4. A history of liver dysfunction after previous methoxyflurane use or other halogenated anesthetics 5. Hypersensitivity to methoxyflurane or other halogenated anesthetics, or to butylated hydroxytoluene 6. Known or genetically susceptible to malignant hyperthermia or a history of severe adverse reactions in either patient or relatives 7. Clinically evident or potential hemodynamic instability as per the opinion of the investigator 8. Clinically evident respiratory impairment as per the opinion of the investigator 9. Prior treatment with PENTHROX® within 3 months

Design outcomes

Primary

Measure	Time frame	Description
Assessing patient satisfaction	through study completion, an average of 1 year	Global assessment of medication performance (gmp)

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026